Professor Alyn
Morice will present an analysis of cough relief in patients
with idiopathic pulmonary fibrosis who were treated with nalbuphine
ER
NEW
HAVEN, Conn., Sept. 26,
2024 /PRNewswire/ -- Trevi Therapeutics, Inc.
(Nasdaq: TRVI), a clinical-stage biopharmaceutical company
developing the investigational therapy Haduvio™ (oral nalbuphine
ER) for the treatment of chronic cough in idiopathic pulmonary
fibrosis (IPF) and refractory chronic cough (RCC), today announced
that data from the Phase 2a CANAL trial will be presented at CHEST
2024 held in Boston, Massachusetts
from October 6-9.
The presentation by Professor Alyn
Morice, Head of Respiratory Medicine at HYMS and leader of
the Hull Cough Clinic, will take place on October 8th and include cough data
from 38 IPF patients who completed at least 1 treatment period of
the CANAL trial. The presentation covers post-hoc analyses of
patients' relief-of-cough duration (any ≥15-minute cough-free
period), cough time (total observation time – relief time), and
cough intensity (number of coughs during coughing time). The
results demonstrated a significant increase in relief-of-cough
time, reduced cough time, and reduced cough intensity in IPF
patients with nalbuphine ER compared with placebo. The safety
results of the trial were generally consistent with the known
safety profile of nalbuphine ER from previous trials. The most
frequently reported treatment-emergent adverse events with
nalbuphine ER treatment were nausea, dizziness, anxiety,
constipation, vomiting, dry mouth, headache, somnolence, dyspnea,
decreased appetite, fatigue and lethargy.
CHEST 2024
October 6 –
9, 2024, Boston, Massachusetts
Session: ILD Abstracts Potpourri
Presentation Date & Time: October
8, 1:51 p.m. – 1:55 p.m. EDT
Location: Convention Center Exhibit Hall, Area 2B
Abstract Accepted for Oral Presentation: Analysis of
Relief-Of-Cough in Patients with Idiopathic Pulmonary Fibrosis
Treated with Oral Nalbuphine Extended Release
Presenter: Professor Alyn
Morice is Head of Respiratory Medicine at HYMS and leader of
the Hull Cough Clinic. Registration details: CHEST Annual
Meeting
About Trevi Therapeutics, Inc.
Trevi Therapeutics,
Inc. is a clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of chronic cough in idiopathic pulmonary fibrosis (IPF)
and refractory chronic cough (RCC). Haduvio is an extended-release
(ER) dual ĸ-opioid receptor agonist and µ-opioid receptor
antagonist that works both centrally in the brain as well as
peripherally in the lungs and has the potential for a synergistic
antitussive effect to treat chronic cough. Parenteral nalbuphine is
not scheduled by the U.S. Drug Enforcement Agency.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. In IPF, chronic cough may lead to worsening disease and may
be associated with a higher risk of progression, death, or need for
lung transplant. There are no approved therapies for the treatment
of chronic cough in IPF and current treatment options provide
minimal benefit to patients. Chronic cough affects up to 10% of the
adult population, and Haduvio's expansion into RCC has the
potential to reach patients suffering from moderate to severe
refractory chronic cough. There are also no approved therapies for
RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral
nalbuphine ER. Its safety and efficacy have not been evaluated by
any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow
Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-additional-analyses-of-cough-relief-time-from-ph2a-canal-trial-accepted-for-oral-presentation-at-chest-2024-302259142.html
SOURCE Trevi Therapeutics, Inc.
